Brominated Flame Retardants vs Advantame: which is worse?

What is Brominated Flame Retardants?

Brominated flame retardants (BFRs) are a class of synthetic chemicals added to consumer products and materials to reduce flammability. They include polybrominated diphenyl ethers (PBDEs), hexabromocyclododecane (HBCD), and others. While not direct food additives, they contaminate the food supply through environmental pathways and food packaging.

What is Advantame?

Advantame is the newest FDA-approved synthetic sweetener, approved in 2014. Like neotame, it is a structural derivative of aspartame but with a vanillin-derived substituent. It is approximately 20,000 times sweeter than sucrose — the most potent sweetener currently approved for food use in the US.

Documented risks

Brominated Flame Retardants: PBDEs and other BFRs are endocrine disruptors, neurodevelopmental toxicants, and probable carcinogens. They accumulate in human adipose tissue, breast milk, and blood. PBDEs were found in 100% of samples in multiple US population biomonitoring studies. US women have PBDE body burdens 10-100 times higher than European women, reflecting the US's historically heavy PBDE use before bans. Neurodevelopmental effects: multiple studies have associated prenatal PBDE exposure with lower IQ, attention deficits, and behavioral problems in children. A 2012 Environmental Health Perspectives study found inverse associations between PBDE cord blood levels and child IQ and behavioral outcomes. Thyroid disruption: BFRs structurally mimic thyroid hormones and compete with thyroid hormone binding proteins, disrupting the thyroid axis — critical for fetal brain development. Carcinogenicity: some PBDEs are associated with thyroid cancer risk in human studies. PBDEs enter the food supply primarily through fatty fish (salmon, tuna), meat, dairy, and some contaminated produce from biosolid-amended soils.

Advantame: Advantame is the newest approved high-intensity sweetener with the least post-approval safety data. The FDA approval was based on extensive pre-market animal studies showing no significant toxicity, carcinogenicity, reproductive toxicity, or neurotoxicity at relevant doses. EFSA approved it for EU use in 2014, finding no safety concerns based on the submitted data. Like other synthetic sweeteners, advantame has not been studied for long-term effects in large human populations post-approval. The same gut microbiome and glucose tolerance concerns raised for other sweeteners (aspartame, sucralose, acesulfame K) have not been specifically studied for advantame, though the class-wide concerns are relevant. Given its 2014 approval date, independent long-term safety studies are still limited.